Literature DB >> 11709085

FcgammaRIIB-mediated inhibition of T-cell receptor signal transduction involves the phosphorylation of SH2-containing inositol 5-phosphatase (SHIP), dephosphorylation of the linker of activated T-cells (LAT) and inhibition of calcium mobilization.

W A Jensen1, S Marschner, V L Ott, J C Cambier.   

Abstract

The low-affinity receptor for immunoglobulin G, FcgammaRIIB, is expressed on most B-cells and on immature and activated mature T-cells. Co-aggregation of FcgammaRIIB with the B-cell antigen receptor (BCR) leads to attenuation of BCR-induced blastogenesis and cell proliferation via inhibition of p21(ras), phosphatidylinositol 3-kinase (PI3-K) and phospholipase Cgamma (PLCgamma) activation. These effects are mediated, at least in part, by the recruitment of SH2-containing protein tyrosine phosphatase-1 (SHP-1) and -2 (SHP-2) and SH2-containing inositol 5-phosphatase (SHIP). In this report, we demonstrate that FcgammaRIIB co-aggregation with the T-cell antigen receptor (TCR), which may occur when T-cells recognize antibody-coated target cells, leads to inhibition of TCR-induced phosphorylation of the linker of activated T-cells (LAT). When phosphorylated, LAT functions as an adapter molecule and recruits PI3-K. Additionally, we demonstrate that PI3-K is required for TCR-induced Ca(2+) mobilization. Together, these data suggest that FcgammaRIIB may inhibit TCR-mediated Ca(2+) mobilization, in part via inhibition of LAT phosphorylation and subsequent inhibition of PI3-K activation. A similar mechanism has been described in B-cells, where FcgammaRIIB co-aggregation with the BCR leads to inhibition of PI3-K activity via dephosphorylation of CD19. It is likely that, in both cell types, levels of PtdIns(3,4,5)P(3) are additionally modulated via the enzymic activity of SHIP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709085     DOI: 10.1042/0300-5127:0290840

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  8 in total

Review 1.  Intravenous immunoglobulin and multiple sclerosis.

Authors:  Anat Achiron; Shmuel Miron
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  KMT1E-mediated chromatin modifications at the FcγRIIb promoter regulate thymocyte development.

Authors:  F J Martin; Y Xu; F Lohmann; D N Ciccone; T B Nicholson; J J Loureiro; T Chen; Q Huang
Journal:  Genes Immun       Date:  2015-01-08       Impact factor: 2.676

Review 3.  The role of basophils as innate immune regulatory cells in allergy and immunotherapy.

Authors:  Salvatore Chirumbolo; Geir Bjørklund; Andrea Sboarina; Antonio Vella
Journal:  Hum Vaccin Immunother       Date:  2018-01-18       Impact factor: 3.452

4.  FcgammaRIIb inhibits allergic lung inflammation in a murine model of allergic asthma.

Authors:  Nilesh Dharajiya; Swapnil V Vaidya; Hiroki Murai; Victor Cardenas; Alexander Kurosky; Istvan Boldogh; Sanjiv A Sur
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

5.  The inhibitory receptor FcgammaRII reduces joint inflammation and destruction in experimental immune complex-mediated arthritides not only by inhibition of FcgammaRI/III but also by efficient clearance and endocytosis of immune complexes.

Authors:  Peter van Lent; Karin C Nabbe; Peter Boross; Arjen B Blom; Johannes Roth; Astrid Holthuysen; Annet Sloetjes; Sjef Verbeek; Wim van den Berg
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 6.  PIP3 pathway in regulatory T cells and autoimmunity.

Authors:  Masaki Kashiwada; Ping Lu; Paul B Rothman
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 7.  Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity.

Authors:  Kirsten M Baecher; Mandy L Ford
Journal:  Cancer Immunol Immunother       Date:  2021-07-09       Impact factor: 6.968

Review 8.  Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance.

Authors:  Ranferi Ocaña-Guzman; Luis Vázquez-Bolaños; Isabel Sada-Ovalle
Journal:  J Immunol Res       Date:  2018-02-11       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.